Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal
Xtandi sales declined 11% in the first quarter due to an increase in the use of patient assistance programs, but demand grew 13%, which management said reflects the underlying strength of the prostate cancer drug.
You may also be interested in...
Following tax reform, analysts expect imminent biopharma mega-mergers, with Pfizer, Merck and Roche looking to buy, AstraZeneca, Bristol and Vertex looming as take-out candidates, and Amgen as either a buyer or a target.
Janssen hasn’t released Phase III data yet but says the next-generation androgen receptor inhibitor showed potential benefit for metastasis-free survival.
Pfizer needed good news from the Phase III PROSPER trial testing Xtandi in non-metastatic prostate cancer patients to show investors the Medivation deal was worth the cost. It got what it was hoping for.